JP2004522700A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2004522700A5 JP2004522700A5 JP2002535654A JP2002535654A JP2004522700A5 JP 2004522700 A5 JP2004522700 A5 JP 2004522700A5 JP 2002535654 A JP2002535654 A JP 2002535654A JP 2002535654 A JP2002535654 A JP 2002535654A JP 2004522700 A5 JP2004522700 A5 JP 2004522700A5
- Authority
- JP
- Japan
- Prior art keywords
- group
- member selected
- alkyl
- methyl
- trivalent
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 125000000217 alkyl group Chemical group 0.000 claims description 10
- 239000003369 serotonin 5-HT3 receptor antagonist Substances 0.000 claims description 3
- 125000004043 oxo group Chemical group O=* 0.000 claims description 2
- 125000003342 alkenyl group Chemical group 0.000 claims 1
- 125000000753 cycloalkyl group Chemical group 0.000 claims 1
- SIKJAQJRHWYJAI-UHFFFAOYSA-N indole Chemical class C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- CGHRJBLSXVCYQF-YXSUXZIUSA-N Dolasetron Chemical compound C1=CC=C[C]2C(C(O[C@@H]3C[C@@H]4C[C@@H]5C[C@@H](N4CC5=O)C3)=O)=CN=C21 CGHRJBLSXVCYQF-YXSUXZIUSA-N 0.000 description 2
- FELGMEQIXOGIFQ-UHFFFAOYSA-N Ondansetron Chemical compound CC1=NC=CN1CC1C(=O)C(C=2C(=CC=CC=2)N2C)=C2CC1 FELGMEQIXOGIFQ-UHFFFAOYSA-N 0.000 description 2
- JSWZEAMFRNKZNL-UHFFFAOYSA-N alosetron Chemical compound N1C=NC(CN2C(C3=C(N(C4=CC=CC=C43)C)CC2)=O)=C1C JSWZEAMFRNKZNL-UHFFFAOYSA-N 0.000 description 2
- MFWNKCLOYSRHCJ-AGUYFDCRSA-N 1-methyl-N-[(1S,5R)-9-methyl-9-azabicyclo[3.3.1]nonan-3-yl]indazole-3-carboxamide Chemical compound C1=CC=C2C(C(=O)NC3C[C@H]4CCC[C@@H](C3)N4C)=NN(C)C2=C1 MFWNKCLOYSRHCJ-AGUYFDCRSA-N 0.000 description 1
- VXVWIFPRBAAZEY-KOEKDOOYSA-M C1=NC2=CC=CC=C2C1(C([O-])=O)[C@@]1(N2C)CC[C@@]2([H])CCC1 Chemical compound C1=NC2=CC=CC=C2C1(C([O-])=O)[C@@]1(N2C)CC[C@@]2([H])CCC1 VXVWIFPRBAAZEY-KOEKDOOYSA-M 0.000 description 1
- 229960003727 Granisetron Drugs 0.000 description 1
- MFWNKCLOYSRHCJ-BTTYYORXSA-N Granisetron Chemical compound C1=CC=C2C(C(=O)N[C@H]3C[C@H]4CCC[C@@H](C3)N4C)=NN(C)C2=C1 MFWNKCLOYSRHCJ-BTTYYORXSA-N 0.000 description 1
- TTWJBBZEZQICBI-UHFFFAOYSA-N Metoclopramide Chemical compound CCN(CC)CCNC(=O)C1=CC(Cl)=C(N)C=C1OC TTWJBBZEZQICBI-UHFFFAOYSA-N 0.000 description 1
- 229960005343 Ondansetron Drugs 0.000 description 1
- NTHPAPBPFQJABD-LLVKDONJSA-N Ramosetron Chemical compound C12=CC=CC=C2N(C)C=C1C(=O)[C@H]1CC(NC=N2)=C2CC1 NTHPAPBPFQJABD-LLVKDONJSA-N 0.000 description 1
- 229960003550 alosetron Drugs 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 229960003413 dolasetron Drugs 0.000 description 1
- KMAKOBLIOCQGJP-UHFFFAOYSA-N indole-3-carboxylic acid Chemical compound C1=CC=C2C(C(=O)O)=CNC2=C1 KMAKOBLIOCQGJP-UHFFFAOYSA-N 0.000 description 1
- 229960004503 metoclopramide Drugs 0.000 description 1
- -1 oct-3-yl Chemical group 0.000 description 1
- 229950001588 ramosetron Drugs 0.000 description 1
- 239000002464 receptor antagonist Substances 0.000 description 1
- ZNRGQMMCGHDTEI-ITGUQSILSA-N tropisetron Chemical compound C1=CC=C2C(C(=O)O[C@H]3C[C@H]4CC[C@@H](C3)N4C)=CNC2=C1 ZNRGQMMCGHDTEI-ITGUQSILSA-N 0.000 description 1
- 229960003688 tropisetron Drugs 0.000 description 1
Description
【0008】
前掲の一般式の範囲内で、特定の実施形態、特にR5、R6、およびR7(これらのうち2個もしくはすべてが同一であってもよく、またはすべてが異なっていてもよい)が、HまたはC1〜C3アルキルのどちらかであり、R9がNであり、R10が二価C2〜C3アルキルでありかつR11がHであるか、あるいはR10およびR11が組み合わされて、C4〜C6三価アルキルまたはオキソ置換C4〜C6三価アルキルのどちらかを形成している実施形態が好ましい。前述の4種類の具体的な5−HT3受容体アンタゴニストは、すべて一般式の範囲内にある。これらの化合物および本発明の範囲内にある他の5−HT3受容体アンタゴニストの分子構造は以下の通りである。
オンダンセトロン:1,2,3,9−テトラヒドロ−9−メチル−3−[(2−メチル−1H−イミダゾール−1−イル)メチル]−4H−カルバゾル−4−オン
【化8】
グラニセトロン:エンド−1−メチル−N−(9−メチル−9−アザビシクロ[3.3.1]ノン−3−イル)−1H−インダゾール−3−カルボキシアミド
【化9】
トロピセトロン:エンド−1H−インドール−3−カルボン酸 8−メチル−8−アザビシクロ[3.3.1]オクト−3−イルエステル
【化10】
ドラセトロン:1H−インドール−3−カルボン酸(2α,6α,8α,9αβ)−オクタヒドロ−3−オキソ−2,6−ジメタノ−2H−キノリジン−8−イルエステル
【化11】
アザセトロン:(±)−N−アザビシクロ[2.2.2]オクト−3−イル−6−クロロ−3,4−ジヒドロ−4−メチル−3−オキソ−1,4−ベンゾオキサジン−8−カルボキシアミド
【化12】
アロセトロン:2,3,4,5−テトラヒドロ−5−メチル−2−[(5−メチル−1H−イミダゾール−4−イル)メチル]−1H−ピリド[4,3−b]インドール−1−オン
【化13】
ラモセトロン
【化14】
本発明を実施する際に使用することができる他の5−HT3受容体アンタゴニストは、ヒドロドラセトロン(ドラセトロンの活性代謝物)、3−トロパニル−インドール−3−カルボキシレートメチオジド、KB−R6933、GK−128、メトクロプラミド、LY−278,584、およびMDL−72222である。
前掲の一般式の範囲内で、特定の実施形態、特にR5、R6、およびR7(これらのうち2個もしくはすべてが同一であってもよく、またはすべてが異なっていてもよい)が、HまたはC1〜C3アルキルのどちらかであり、R9がNであり、R10が二価C2〜C3アルキルでありかつR11がHであるか、あるいはR10およびR11が組み合わされて、C4〜C6三価アルキルまたはオキソ置換C4〜C6三価アルキルのどちらかを形成している実施形態が好ましい。前述の4種類の具体的な5−HT3受容体アンタゴニストは、すべて一般式の範囲内にある。これらの化合物および本発明の範囲内にある他の5−HT3受容体アンタゴニストの分子構造は以下の通りである。
オンダンセトロン:1,2,3,9−テトラヒドロ−9−メチル−3−[(2−メチル−1H−イミダゾール−1−イル)メチル]−4H−カルバゾル−4−オン
【化8】
グラニセトロン:エンド−1−メチル−N−(9−メチル−9−アザビシクロ[3.3.1]ノン−3−イル)−1H−インダゾール−3−カルボキシアミド
【化9】
トロピセトロン:エンド−1H−インドール−3−カルボン酸 8−メチル−8−アザビシクロ[3.3.1]オクト−3−イルエステル
【化10】
ドラセトロン:1H−インドール−3−カルボン酸(2α,6α,8α,9αβ)−オクタヒドロ−3−オキソ−2,6−ジメタノ−2H−キノリジン−8−イルエステル
【化11】
アザセトロン:(±)−N−アザビシクロ[2.2.2]オクト−3−イル−6−クロロ−3,4−ジヒドロ−4−メチル−3−オキソ−1,4−ベンゾオキサジン−8−カルボキシアミド
【化12】
アロセトロン:2,3,4,5−テトラヒドロ−5−メチル−2−[(5−メチル−1H−イミダゾール−4−イル)メチル]−1H−ピリド[4,3−b]インドール−1−オン
【化13】
ラモセトロン
【化14】
本発明を実施する際に使用することができる他の5−HT3受容体アンタゴニストは、ヒドロドラセトロン(ドラセトロンの活性代謝物)、3−トロパニル−インドール−3−カルボキシレートメチオジド、KB−R6933、GK−128、メトクロプラミド、LY−278,584、およびMDL−72222である。
Claims (1)
- 前記5−ヒドロキシトリプタミン−3受容体アンタゴニストが下式を有する置換1H−インドールである請求項1に記載の薬剤組成物。
R2およびR3は組み合わされて、下式からなる群から選択される式を有する二価の構造を形成するか、
あるいはR2はNおよびCHからなる群から選択されるメンバーであり、R3は下式の構造である。
R10は低級二価アルキルでありかつR11はHまたは低級アルキルからなる群から選択されるメンバーであり、
あるいはR10およびR11は組み合わされて、低級三価アルキルおよびオキソ置換低級三価アルキルからなる群から選択される三価構造を形成する。))
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US09/691,398 US6451808B1 (en) | 2000-10-17 | 2000-10-17 | Inhibition of emetic effect of metformin with 5-HT3 receptor antagonists |
PCT/US2001/042751 WO2002032416A2 (en) | 2000-10-17 | 2001-10-16 | Inhibition of emetic effect of metformin with 5-ht3 receptor antagonists |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2004522700A JP2004522700A (ja) | 2004-07-29 |
JP2004522700A5 true JP2004522700A5 (ja) | 2005-04-07 |
Family
ID=24776400
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2002535654A Pending JP2004522700A (ja) | 2000-10-17 | 2001-10-16 | 5−ht3受容体アンタゴニストによるメトホルミンの催吐作用の阻害 |
Country Status (14)
Country | Link |
---|---|
US (1) | US6451808B1 (ja) |
EP (1) | EP1326643B1 (ja) |
JP (1) | JP2004522700A (ja) |
KR (1) | KR100907640B1 (ja) |
AT (1) | ATE314090T1 (ja) |
AU (2) | AU1192302A (ja) |
CA (1) | CA2422711C (ja) |
DE (1) | DE60116353T2 (ja) |
ES (1) | ES2251516T3 (ja) |
IL (1) | IL154988A0 (ja) |
MX (1) | MXPA03003128A (ja) |
NZ (1) | NZ524790A (ja) |
PT (1) | PT1326643E (ja) |
WO (1) | WO2002032416A2 (ja) |
Families Citing this family (79)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TWI312285B (en) | 2001-10-25 | 2009-07-21 | Depomed Inc | Methods of treatment using a gastric retained gabapentin dosage |
US20070184104A1 (en) * | 2001-10-25 | 2007-08-09 | Depomed, Inc. | Gastric retentive gabapentin dosage forms and methods for using same |
CA2409552A1 (en) | 2001-10-25 | 2003-04-25 | Depomed, Inc. | Gastric retentive oral dosage form with restricted drug release in the lower gastrointestinal tract |
JP2005508358A (ja) * | 2001-10-25 | 2005-03-31 | デポメド・インコーポレイテッド | 胃滞留型ロサルタン投与量を用いる治療方法 |
US20030152622A1 (en) * | 2001-10-25 | 2003-08-14 | Jenny Louie-Helm | Formulation of an erodible, gastric retentive oral diuretic |
US20030104052A1 (en) * | 2001-10-25 | 2003-06-05 | Bret Berner | Gastric retentive oral dosage form with restricted drug release in the lower gastrointestinal tract |
US20030091630A1 (en) * | 2001-10-25 | 2003-05-15 | Jenny Louie-Helm | Formulation of an erodible, gastric retentive oral dosage form using in vitro disintegration test data |
US7612112B2 (en) * | 2001-10-25 | 2009-11-03 | Depomed, Inc. | Methods of treatment using a gastric retained gabapentin dosage |
EP1527328B1 (en) * | 2002-07-20 | 2009-09-09 | Acea Biosciences, Inc. | Impedance based apparatuses and methods for analyzing cells and particles |
EP1558081A4 (en) | 2003-01-13 | 2006-06-14 | Dynogen Pharmaceuticals Inc | METHOD OF TREATING FUNCTIONAL INTESTINAL DISORDERS |
AU2004285531A1 (en) * | 2003-10-31 | 2005-05-12 | Alza Corporation | Compositions and dosage forms for enhanced absorption of metformin |
WO2006066748A1 (en) * | 2004-12-21 | 2006-06-29 | F. Hoffmann-La Roche Ag | Tetralin and indane derivatives and uses thereof as 5-ht antagonists |
US20070021379A1 (en) | 2005-07-11 | 2007-01-25 | Pharmena North America Inc. | Methylnicotinamide derivatives and formulations for treatment of lipoprotein abnormalities |
US20090176882A1 (en) * | 2008-12-09 | 2009-07-09 | Depomed, Inc. | Gastric retentive gabapentin dosage forms and methods for using same |
WO2010129686A1 (en) | 2009-05-05 | 2010-11-11 | Vapogenix, Inc. | Novel formulations of volatile anesthetics and methods of use for reducing inflammation |
CN103347517B (zh) | 2010-08-11 | 2018-10-02 | 德雷克塞尔大学 | 治疗帕金森病中运动障碍的d3多巴胺受体激动剂 |
US8944342B2 (en) | 2010-11-02 | 2015-02-03 | M&R Consulting Services, Inc. | Two-part, wall-mountable electrochemical dispenser |
US8435993B2 (en) | 2010-12-07 | 2013-05-07 | Philadelphia Health And Education Corporation | Methods of inhibiting metastasis from cancer |
US11759441B2 (en) | 2011-01-07 | 2023-09-19 | Anji Pharmaceuticals Inc. | Biguanide compositions and methods of treating metabolic disorders |
US8796338B2 (en) | 2011-01-07 | 2014-08-05 | Elcelyx Therapeutics, Inc | Biguanide compositions and methods of treating metabolic disorders |
RS61153B1 (sr) | 2011-01-07 | 2020-12-31 | Anji Pharma Us Llc | Ligand hemosenzornog receptora-osnovne terapije |
US11974971B2 (en) | 2011-01-07 | 2024-05-07 | Anji Pharmaceuticals Inc. | Compositions and methods for treating metabolic disorders |
US9211263B2 (en) | 2012-01-06 | 2015-12-15 | Elcelyx Therapeutics, Inc. | Compositions and methods of treating metabolic disorders |
US9480663B2 (en) | 2011-01-07 | 2016-11-01 | Elcelyx Therapeutics, Inc. | Biguanide compositions and methods of treating metabolic disorders |
US9572784B2 (en) | 2011-01-07 | 2017-02-21 | Elcelyx Therapeutics, Inc. | Compositions comprising statins, biguanides and further agents for reducing cardiometabolic risk |
US8476221B2 (en) | 2011-03-18 | 2013-07-02 | Halimed Pharmaceuticals, Inc. | Methods and compositions for the treatment of metabolic disorders |
US20130143867A1 (en) | 2011-12-02 | 2013-06-06 | Sychroneuron Inc. | Acamprosate formulations, methods of using the same, and combinations comprising the same |
KR20190007106A (ko) | 2011-12-21 | 2019-01-21 | 노비라 테라퓨틱스, 인코포레이티드 | B형 간염의 항바이러스성 제제 |
CN110693868A (zh) | 2012-01-06 | 2020-01-17 | 埃尔舍利克斯治疗公司 | 双胍组合物和治疗代谢性病症的方法 |
KR102231554B1 (ko) | 2012-01-06 | 2021-03-23 | 앤지 파마 유에스 엘엘씨 | 대사 장애를 치료하는 조성물 및 방법 |
JP6397407B2 (ja) | 2012-07-19 | 2018-09-26 | ドレクセル ユニバーシティ | 細胞タンパク質ホメオスタシスを調節するためのシグマ受容体リガンド |
US9555012B2 (en) | 2012-08-09 | 2017-01-31 | Dynamis Therapeutics, Inc. | Methods for maintaining or improving health, well-being and/or a physiological function in a subject |
RS61101B1 (sr) | 2013-01-07 | 2020-12-31 | Univ Pennsylvania | Preparati i postupci za lečenje kožnog limfoma t-ćelija |
EP3878445A3 (en) | 2013-06-05 | 2021-10-27 | Synchroneuron Inc. | Acamprosate formulations, methods of using the same, and combinations comprising the same |
ES2769893T3 (es) | 2013-07-02 | 2020-06-29 | Ecoplanet Env Llc | Formulaciones de compuestos orgánicos volátiles que tienen actividad antimicrobiana |
GB201311888D0 (en) | 2013-07-03 | 2013-08-14 | Glaxosmithkline Ip Dev Ltd | Novel compounds |
GB201311891D0 (en) | 2013-07-03 | 2013-08-14 | Glaxosmithkline Ip Dev Ltd | Novel compound |
EP3074049B1 (en) | 2013-11-26 | 2020-05-06 | Yale University | Novel cell-penetrating compositions and methods using same |
WO2015089049A1 (en) | 2013-12-09 | 2015-06-18 | Thomas Jefferson University | Novel methods of treating a neurodegenerative disease in a mammal in need thereof |
EP3128996B1 (en) | 2014-04-07 | 2021-06-02 | University of Rochester | Novel 7-dehydrocholesterol derivatives and methods using same |
CA2968215A1 (en) | 2014-08-20 | 2016-02-25 | Yale University | Novel compositions and methods useful for treating or preventing liver diseases or disorders, and promoting weight loss |
US9695517B2 (en) | 2014-12-29 | 2017-07-04 | M & R Consulting Services, Inc. | Two-part, wall-mountable electrochemical dispenser |
US9931344B2 (en) * | 2015-01-12 | 2018-04-03 | Nano Pharmaceutical Laboratories, Llc | Layered sustained-release microbeads and methods of making the same |
US10597368B2 (en) | 2015-05-08 | 2020-03-24 | Brown University | Syringolin analogues and methods of making and using same |
JP6995627B2 (ja) | 2015-05-19 | 2022-02-04 | イエール ユニバーシティ | 病的石灰化状態を治療するための組成物およびそれを使用する方法 |
US10829440B2 (en) | 2015-06-12 | 2020-11-10 | Brown University | Antibacterial compounds and methods of making and using same |
CN107708701A (zh) | 2015-06-30 | 2018-02-16 | 纽拉德有限公司 | 新颖呼吸控制调节化合物以及其制备和使用方法 |
WO2017075145A1 (en) | 2015-10-28 | 2017-05-04 | Yale University | Quinoline amides and methods of using same |
EP4079322A1 (en) | 2015-11-20 | 2022-10-26 | Yale University | Compositions for treating ectopic calcification disorders, and methods using same |
US20190119364A1 (en) | 2016-04-29 | 2019-04-25 | The Regents Of The University Of Colorado, A Body Corporate | Compounds and compositions useful for treating metabolic syndrome, and methods using same |
WO2018026764A1 (en) | 2016-08-01 | 2018-02-08 | University Of Rochester | Nanoparticles for controlled release of anti-biofilm agents and methods of use |
AU2017306549A1 (en) | 2016-08-05 | 2019-02-21 | Yale University | Compositions and methods for stroke prevention in pediatric sickle cell anemia patients |
EP3506983B1 (en) | 2016-09-01 | 2021-08-25 | Mebias Discovery, Inc. | Substituted urea-derivatives for the treatment of pain |
CA3040919A1 (en) | 2016-11-07 | 2018-05-11 | Arbutus Biopharma Corporation | Substituted pyridinone-containing tricyclic compounds, and methods using same |
EP4219486A1 (en) | 2017-01-19 | 2023-08-02 | Temple University of the Commonwealth System of Higher Education | Novel bridged bicycloalkyl-substituted aminothizoles and their methods of use |
MA49014A (fr) | 2017-03-21 | 2020-02-05 | Arbutus Biopharma Corp | Dihydroindène-4-carboxamides substitués, leurs analogues et procédés d'utilisation correspondant |
EP3612184A4 (en) | 2017-04-17 | 2021-01-20 | Yale University | COMPOUNDS, COMPOSITIONS AND METHODS FOR THE TREATMENT OR PREVENTION OF ACUTE LUNG INJURY |
CA3071345A1 (en) | 2017-07-28 | 2019-01-31 | Yale University | Anticancer drugs and methods of making and using same |
CA3074017A1 (en) | 2017-09-08 | 2019-03-14 | The Regents Of The University Of Colorado, A Body Corporate | Compounds, compositions and methods for treating or preventing her-driven drug-resistant cancers |
EP3716985A1 (en) | 2017-11-27 | 2020-10-07 | The U.S.A. As Represented By The Secretary, Department Of Health And Human Services | Compounds, compositions, and methods for treating and/or preventing periodontal disease |
WO2019125184A1 (en) | 2017-12-19 | 2019-06-27 | Auckland Uniservices Limited | Use of biomarker in cancer therapy |
CA3089236A1 (en) | 2018-01-24 | 2019-08-01 | The Rockefeller University | Antibacterial compounds, compositions thereof, and methods using same |
EA202092691A1 (ru) | 2018-05-29 | 2021-04-21 | Церси Терапьютикс, Инк. | Соединения для устранения боли, композиции, содержащие их, и способы их применения |
KR102651652B1 (ko) | 2018-10-11 | 2024-03-26 | 사니핏 테라퓨틱스 에스.에이. | 이소성 석회화의 치료를 위한 이노시톨 포스페이트 |
TWI827760B (zh) | 2018-12-12 | 2024-01-01 | 加拿大商愛彼特生物製藥公司 | 經取代之芳基甲基脲類及雜芳基甲基脲類、其類似物及其使用方法 |
KR20210148078A (ko) | 2019-01-30 | 2021-12-07 | 사니핏 테라퓨틱스 에스.에이. | 조직 관류 증가에 사용하기 위한 이노시톨 포스페이트 화합물 |
WO2020159565A1 (en) | 2019-02-01 | 2020-08-06 | Cersci Therapeutics, Inc. | Methods of treating post-surgical pain with a thiazoline anti-hyperalgesic agent |
US20200246317A1 (en) | 2019-02-01 | 2020-08-06 | Cersci Therapeutics, Inc. | Methods of treating diabetic neuropathy with a thiazoline anti-hyperalgesic agent |
US11471508B2 (en) | 2019-05-09 | 2022-10-18 | The Feinstein Institutes For Medical Research | HMGB1 antagonist treatment of diabetic peripheral neuropathy |
US11555010B2 (en) | 2019-07-25 | 2023-01-17 | Brown University | Diamide antimicrobial agents |
EP3818983A1 (en) | 2019-11-11 | 2021-05-12 | Sanifit Therapeutics S.A. | Inositol phosphate compounds for use in treating, inhibiting the progression, or preventing cardiovascular calcification |
WO2021127456A1 (en) | 2019-12-19 | 2021-06-24 | Rain Therapeutics Inc. | Methods of inhibiting epidermal growth factor receptor proteins |
CA3181983A1 (en) | 2020-06-09 | 2021-12-16 | Zhiliang Cheng | Soluble enpp1 or enpp3 proteins and uses thereof |
EP4015494A1 (en) | 2020-12-15 | 2022-06-22 | Sanifit Therapeutics S.A. | Processes for the preparation of soluble salts of inositol phosphates |
EP4036097A1 (en) | 2021-01-29 | 2022-08-03 | Sanifit Therapeutics S.A. | Ip4-4,6 substituted derivative compounds |
WO2023278300A1 (en) * | 2021-06-28 | 2023-01-05 | ImmunoMet Therapeutics, Inc. | Solid dosage form of n-1-pyrrolidine-n-5-(3-trifluoromethoxy)phenyl biguanide and uses thereof |
WO2024023360A1 (en) | 2022-07-29 | 2024-02-01 | Sanifit Therapeutics, S.A. | Ip5 substituted compounds |
WO2024023359A1 (en) | 2022-07-29 | 2024-02-01 | Sanifit Therapeutics, S.A. | Ip4-4,6 substituted derivative compounds for use in the treatment, inhibition of progression, and prevention of ectopic calcification |
WO2024052895A1 (en) | 2022-09-06 | 2024-03-14 | Hadasit Medical Research Services And Development Ltd | Combinations comprising psychedelics for the treatment of schizophrenia and other neuropsychiatric and neurologic disorders |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS5936675A (ja) | 1982-07-13 | 1984-02-28 | サンド・アクチエンゲゼルシヤフト | 二環性複素環式カルボン酸アザビシクロアルキルエステルまたはアミド |
US4695578A (en) | 1984-01-25 | 1987-09-22 | Glaxo Group Limited | 1,2,3,9-tetrahydro-3-imidazol-1-ylmethyl-4H-carbazol-4-ones, composition containing them, and method of using them to treat neuronal 5HT function disturbances |
WO1992003122A1 (de) * | 1990-08-24 | 1992-03-05 | Gregor Cevc | Präparat zur wirkstoffapplikation in kleinsttröpfchenform |
US5576306A (en) | 1991-03-01 | 1996-11-19 | Dow Chemical Company | Pharmaceutical compositions and uses of water-soluble, high-viscosity grade cellulose ethers |
DE4432757A1 (de) | 1994-09-14 | 1996-03-21 | Boehringer Mannheim Gmbh | Pharmazeutische Zubereitung enthaltend Metformin und Verfahren zu deren Herstellung |
ATE261935T1 (de) | 1997-12-08 | 2004-04-15 | Bristol Myers Squibb Co | Neue metformin salze und verfahren |
-
2000
- 2000-10-17 US US09/691,398 patent/US6451808B1/en not_active Expired - Lifetime
-
2001
- 2001-10-16 DE DE60116353T patent/DE60116353T2/de not_active Expired - Lifetime
- 2001-10-16 MX MXPA03003128A patent/MXPA03003128A/es active IP Right Grant
- 2001-10-16 AU AU1192302A patent/AU1192302A/xx active Pending
- 2001-10-16 WO PCT/US2001/042751 patent/WO2002032416A2/en active Search and Examination
- 2001-10-16 JP JP2002535654A patent/JP2004522700A/ja active Pending
- 2001-10-16 KR KR1020037005263A patent/KR100907640B1/ko active IP Right Grant
- 2001-10-16 NZ NZ524790A patent/NZ524790A/en not_active IP Right Cessation
- 2001-10-16 IL IL15498801A patent/IL154988A0/xx unknown
- 2001-10-16 EP EP01980020A patent/EP1326643B1/en not_active Expired - Lifetime
- 2001-10-16 PT PT01980020T patent/PT1326643E/pt unknown
- 2001-10-16 AT AT01980020T patent/ATE314090T1/de not_active IP Right Cessation
- 2001-10-16 ES ES01980020T patent/ES2251516T3/es not_active Expired - Lifetime
- 2001-10-16 AU AU2002211923A patent/AU2002211923B2/en not_active Ceased
- 2001-10-16 CA CA002422711A patent/CA2422711C/en not_active Expired - Fee Related
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2004522700A5 (ja) | ||
US5225407A (en) | 5-HT3 receptor antagonists for the treatment of autism | |
EP0804196B1 (en) | Use of serotonin antagonists (5ht 3) for treating fibromyalgia | |
ES2149767T5 (es) | Nuevo uso medico para antagonistas de taquiquininas. | |
JP2009522206A5 (ja) | ||
JP2006505581A5 (ja) | ||
HUP0203458A2 (hu) | Nociceptin ORL-1 receptor agonisták alkalmazása köhögés kezelésére és ezeket tartalmazó gyógyszerkészítmények | |
JP2007332141A5 (ja) | ||
JP2015512888A5 (ja) | ||
JP2010509391A5 (ja) | ||
JP2010539151A5 (ja) | ||
JPS63277622A (ja) | 医薬 | |
WO1991009593A2 (en) | 5-ht3 antagonists for treatment of nausea, bradycardia of hypotension associated with myocardial instability | |
US10307409B2 (en) | Muscarinic combinations and their use for combating hypocholinergic disorders of the central nervous system | |
JPS63277623A (ja) | 医薬 | |
US5330982A (en) | Pharmaceutical composition containing a 5-HT receptor antagonist and an H+ K+ Atpase inhibitor and a method of treating gastrointestingal disorders therewith | |
WO2008014360A3 (en) | Modulators of chemokine receptor activity, crystalline forms and process | |
JP2007532671A5 (ja) | ||
JP2007522202A5 (ja) | ||
TWI317360B (en) | Heteroaryl derivatives as superior ligands for nociceptin receptor orl-1 | |
US20180250270A1 (en) | Muscarinic combination and its use for combating hypocholinergic disorders of the central nervous system | |
JP2014521620A5 (ja) | ||
JP2011504936A5 (ja) | ||
CA1314223C (en) | Composition for treating gastrointestinal disorders | |
JP2011507836A5 (ja) |